Mudra Rakshasa-Loots, Arish http://orcid.org/0000-0003-1860-3865
Bakewell, Nicholas
Sharp, David J.
Gisslén, Magnus
Zetterberg, Henrik
Alagaratnam, Jasmini
Wit, Ferdinand W. N. M. http://orcid.org/0000-0003-2066-8115
Kootstra, Neeltje A.
Winston, Alan
Reiss, Peter http://orcid.org/0000-0001-7896-6428
Sabin, Caroline A.
Vera, Jaime H.
,
Article History
Received: 5 January 2023
Revised: 19 May 2023
Accepted: 26 May 2023
First Online: 6 June 2023
Competing interests
: AMRL, NB, DS, FW, NAK and JHV have no competing interests to declare. JA has received financial support to attend scientific conferences from MSD, Janssen UK and Gilead Sciences. HZ has served at scientific advisory boards and/or as a consultant for Abbvie, Acumen, Alector, Alzinova, ALZPath, Annexon, Apellis, Artery Therapeutics, AZTherapies, CogRx, Denali, Eisai, Nervgen, Novo Nordisk, Passage Bio, Pinteon Therapeutics, Prothena, Red Abbey Labs, reMYND, Roche, Samumed, Siemens Healthineers, Triplet Therapeutics, and Wave, has given lectures in symposia sponsored by Cellectricon, Fujirebio, Alzecure, Biogen, and Roche, and is a co-founder of Brain Biomarker Solutions in Gothenburg AB (BBS), which is a part of the GU Ventures Incubator Program (outside submitted work). MG has received research grants from Gilead Sciences and Janssen-Cilag and honoraria as speaker, DSMB committee member and/or scientific advisor from Amgen, AstraZeneca, Biogen, Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline/ViiV, Janssen-Cilag, MSD, Novocure, Novo Nordic, Pfizer and Sanofi. PR through his institution has received independent scientific grant support from Gilead Sciences, Janssen Pharmaceuticals Inc., Merck & Co and ViiV Healthcare, and has served on scientific advisory boards for Gilead Sciences, ViiV Healthcare, and Merck & Co., for which honoraria were all paid to his institution. AW has received honoraria or research grants on behalf of Imperial College London or been a consultant or investigator in clinical trials sponsored by Bristol-Myers Squibb, Gilead Sciences, GlaxoSmithKline, Janssen-Cilag, Roche and ViiV Healthcare. CAS has received funding for the membership of Data Safety and Monitoring Boards, Advisory Boards and for the preparation of educational materials from Gilead Sciences and ViiV Healthcare.